Breaking News

Tigermed Gains Majority Stake in Frontage

August 5, 2014

Partnership establishes global clinical trial network

Hangzhou Tigermed Consulting Co., Ltd. and Frontage Laboratories, Inc. have completed an investment agreement, following approval by the China Securities and Regulatory Commission, under which Tigermed has acquired a majority stake in Frontage, a provider of bioanalysis, preclinical studies, early phase clinical studies and product development services for biopharma companies. Tigermed provides outsourced clinical development services across China and Asia Pacific regions.
Frontage will continue to operate independently, and will retain its name, management team and operations facilities.
“Our strategic partnership with Frontage firmly establishes our global clinical trial network,” said Dr. Xiaoping Ye, founder and chief executive officer of Tigermed. “The two companies share similar philosophies and operational approaches, which combined with additional complementary strengths in research integrity and reliability will now benefit clients on a much larger scale.”
“Joining efforts with Tigermed allows us to expand our geographic range and align our early development services with Tigermed’s late phase clinical operations for a scope that will serve clients looking for full-service, high quality, global drug development resources,” said Song Li, founder and chief executive officer of Frontage.

blog comments powered by Disqus
  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.

  • Cold-Chain Logistics & The Central Lab

    Kristin Brooks, Associate Editor||January 28, 2016
    Eric Hayashi of LabConnect discusses safety measures to ensure sample integrity

  • A Look at DCAT Week ‘16

    Tim Wright, Editor||January 28, 2016
    On the pulse of the pharmaceutical manufacturing value chain, DCAT Week ‘16 will deliver top-flight education programs and networking events.